Switching off HER-2/neu in a Tetracycline-Controlled Mouse Tumor Model Leads to Apoptosis and Tumor-Size-Dependent Remission

Cancer Research

Volumn 63, Issue 21, 2003, Pages 7221-7231

  Schiffer, Ilka B ^a   Gebhard, Susanne ^a   Heimerdinger, Carolin K ^a   Heling, Annette ^a   Hast, Jochem ^a   Wollscheid, Ursula ^a   Seliger, Barbara ^a   Tanner, Berno ^a   Gilbert, Sandra ^b   Beckers, Thomas ^c   Baasner, Silke ^d   Brenner, Walburgis ^a   Spangenberg, Christian ^a   Prawitt, Dirk ^a   Trost, Tatjana ^a   Schreiber, Wolfgang G ^a   Zabel, Bernhard ^a   Thelen, Manfred ^a   Lehr, Hans Anton ^a   Oesch, Franz ^a   Hengstler, Jan G ^e   more..

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Baxter Oncology GmbH   (Germany)

^c Atlanta Pharma   (Germany)

^d Zentaris GmbH   (Germany)

^e UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANHYDROTETRACYCLINE; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN TYROSINE KINASE; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; FEMALE; FIBROBLAST; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SWITCHING; GENE THERAPY; HUMAN; HUMAN CELL; IN VIVO STUDY; KRUSKAL WALLIS TEST; LONG TERM EXPOSURE; MOLECULAR MECHANICS; MOUSE; NICK END LABELING; NONHUMAN; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; RECURRENT CANCER; REMISSION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL DIVISION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NIH 3T3 CELLS; PROMOTER REGIONS (GENETICS); RECEPTOR, ERBB-2; TETRACYCLINE; TETRACYCLINES;

EID: 10744230388     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Rubin, I., and Yarden, Y. The basic biology of HER2. Ann. Oncol., 12: S3-S8, 2001.
2. El-Deiry, W. S. Akt takes centre stage in cell-cycle deregulation. Nat. Cell Biol., 3:E71-73, 2001.
3. Tzahar, E., Pinkas-Kramarski, R., Moyer, J. D., Klapper, L. N., Alroy, I., Levkowitz, G., Shelly, M., Henis, S., Eisenstein, M., Ratzkin, B. J., Sela, M., Andrews, G. C., and Yarden. Y. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J., 16: 4938-4950, 1997.
4. Olayioye, M. A., Neve, R. M., Lane, H. A., and Hynes, N. E. The ErbB signaling network, receptor heterodimerization in development and cancer. EMBO J., 19: 3159-3167, 2000.
5. Muthuswamy, S. K., Gilman, M., and Brugge, J. S. Controlled dimerization of erbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol. Cell. Biol., 19: 6845-6857, 1999.
6. Busse, D., Doughty, S., and Arteaga, C. L. HER-2/neu (erbB-2) and the cell cycle. Semin. Oncol., 27: 3-8, 2000.
7. Harari, D., and Yarden, Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene, 19: 6102-6114, 2000.
8. Zhou, B. P., Hu, M. C. T., Miller, S. A., Yu, Z., Xia, W., Lin, S. Y., and Hung, M. C. HER-2/neu blocks tumor necrosis factor- induced apoptosis via the Akt/NF-κB pathway. J. Biol. Chem., 275: 8027-8031, 2000.
9. Cip/WAF1 by Akt-induced phosphorylation in HER-2/neu overexpressing cells. Nat. Cell Biol., 3: 245-252, 2001.
10. Reese, D. M., and Slamon, D. J. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells. 15: 1-8, 1997.
11. Seliger, B., Rongcun, Y., Atkins, D., Hammers, S., Huber, C., Storkel, S., and Kiessling, R. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int. J. Cancer, 87: 349-359, 2000.
12. Hengstler, J. G., Lange, J., Kett, A., Domhofer, N., Meinert, R., Arand, M., Knapstein, P. G., Becker, R., Oesch, F., and Tanner, B. Contribution of c-erbB-2 and topoisomerase 11α to chemoresistance in ovarian cancer. Cancer Res., 59: 3206-3214, 1999.
13. Micke, P., Hengstler, J. G., Oesch, F., and Buhl, R. C-erbB-2 expression in small-cell lung cancer is associated with poor prognosis. Int. J. Cancer, 92: 474-479, 2001.
14. Citri, A., Alroy, I., Lavi, S., Rubin, C., Xu, W., Grammatikakis, N., Patterson, C., Neckers, L., Fry, D. W., and Yarden, Y. Drug-induced ubiquitilation and degradation of ErbB receptor tyrosine kinases, implications for cancer therapy. EMBO J., 21: 2407-2417, 2002.
15. Park, B. W., Zhang, H. A. T., Wu, C., Berezov, A., Zhang, X., Dua, R., Wang, Q., Gary, K., O'Rourke, D. M., Greene, M. I., and Murali, R. Rationally designed anti-HER2/neu peptide mimetic disables in vitro and in vivo. Nat. Biotechnol., 18: 194-198, 2000.
16. Cuello, M., Ettenberg, S. A., Clark, A. S., Keane, M. M., Posner, R. H., Nau, M. M., Dennis, P. A., and Lipkowitz, S. Down-regulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res., 61: 4892-4900, 2001.
17. Burris, H. A. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin. Oncol., 28: 38-44, 2001.
18. Baselga, J. Clinical trials of Herceptin (trastuzumab). Eur. J. Cancer, 37: 18-24, 2001.
19. Stebbing, J., Copson, E., and O'Reilly, S. Herceptin (trastuzumab) in advanced breast cancer. Cancer Treat Rev., 26: 287-290, 2000.
20. Dickmann, S. Antibodies stage a comeback in cancer treatment. Science (Wash. DC), 280: 1196-1187, 1998.
21. Baasner, S., Melchner, H., Klenner, T., Hilgard, P., and Beckers, T. Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase. Oncogene, 13: 901-911, 1996.
22. Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., and Bujard, H. Transcriptional activation by tetracyclines in mammalian cells. Science (Wash. DC), 268: 1766-1769, 1995.
23. Hast, J., Schiffer, I. B., Neugebauer, B., Teichmann, E., Schreiber, W., Brieger, J., Kim, D. W., Gebhard, S., Born, C. B., Strugala, M., Sagemüller, J., Brenner, W., Mann, W. J., Oesch, F., Thelen, M., and Hengstler, J. G. Angiogenesis and fibroblasts proliferation precede formation of recurrent tumors after radiation therapy in nude mice. Anticancer Res., 22: 677-688, 2002.
24. Radford, M. M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
25. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
26. Schreurs, O., Hasltensen, T. S., Dembic, Z., Bogen, B., and Schenck, K. Fixation of tissue sections for TUNEL combined with staining for thymic epithelial cell marker. Biochemica, 4: 19-21, 1997.
27. Paik, S., Bryant, J., Tan-Chiu, E., Romond, E., Hiller, W., Park, K., Brown, A., Yothers, G., Anderson, S., Smith, R., Wickerkam, D. L., and Wolmark, N. Real-world performance of HER2 testing-National surgical adjuvant breast and bowel project experience. J. Natl. Cancer Inst. (Bethesda), 94: 788-789, 2002.
28. Osoba, D., Slamon, D. J., Burchmore, M., and Murphy, M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J. Clin. Oncol., 20: 3106-3113, 2002.
29. Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., and Jain, R. K. Tumor biology. Herceptin acts a san anti-angiogenic cocktail. Nature (London), 416: 279-280, 2002.
30. Munster, P. N., Marchion, D. C., Basso, A. D., and Rosen, N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-Akt-dependent pathway. Cancer Res., 62: 3132-3137, 2002.
31. Hsieh, S. S., Malerczyk, C., Aigner, A., and Czubayko, F. ErbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation. Int. J. Cancer, 86: 644-651, 2000.
32. Ueno, N. T., Bartholomeusz, C., Herrmann, J. L., Estrov, Z., Shao, R., Andreeff, M., Price, J., Paul, R. W., Anklesaria, P., Yu, D., and Hung, M. C. E1A-mediated paclitaxel sensitization in HER-2/neu overexpressing ovarian cancer SKOV3, ip1 through apoptosis involving the caspase-3 pathway. Clin. Cancer Res., 6: 250-259, 2000.
33. Nelson, J. M., and Fry, D. W. Akt, MAPK (Erk1/2) and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J. Biol. Chem., 276: 14842-14847, 2001.
34. Roh, H., Pippin, J., and Drebin, J. A. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER/neu. Cancer Res., 60: 560-565, 2000.
35. Zhou, Z., Jia, S. F., Hung, M. C., and Kleinerman, E. S. E1A sensitizes HER/neu overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs. Cancer Res., 61: 3394-3398, 2001.
36. Hortobagyi, G. N., Ueno, N. T., Xia, W., Zhang, S., Wolf, J. K., Putnam, J. B., Weiden, P. L., Willey, J. S., Carey, M., Branham, D. L., Payne, J. Y., Tucker, S. D., Bartholomeusz, C., Kilbourn, R. G., De Jager, R. L., Sneige, N., Katz, R. L., Anklesaria, P., Ibrahim, N. K., Murray, J. L., Theriault, R. L., Valero, V., Gershenson, D. M., Bevers, M. W., Huang, L., Lopez-Berestein, B., and Hung, M. C. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase 1 clinical trial. J. Clin. Oncol., 19: 3422-3433, 2001.
37. Daly, J. M., Olayioye, M. A., Wong, A. M. L., Neve, R., Lane, H. A., Maurer, F., and Hynes, N. E. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumor cells, role of P13-kinase and p38 MAP kinase pathways. Oncogene, 18: 3440-3451, 1999.
38. Casalini, P., Botta, L., and Ménard, S. Role of p53 in HER2-induced proliferation or apoptosis. J. Biol. Chem., 276: 12449-124453, 2001.
39. Lazar, H., Baltzer, A., Gimmi, C., Marti, A., and Jaggi, R. Over-expression of erbB-2/neu is paralleled by inhibition of mouse-mammary-epithelial-cell differentiation and developmental apoptosis. Int. J. Cancer, 85: 578-583, 2000.
40. Cahill, D. P., Lengauer, C., Yu, J., Riggins, G. J., Willson, J. K., Markowitz, S. D., Kinzler, K. W., and Vogerlstein, B. Mutations of mitotic checkpoint genes in human cancers. Nature (Lond.), 392: 223-224, 1998.
41. Lengauer, C., Kinzler, K. W., and Vogelstein, B. Genetic instabilities in human cancers. Nature (Lond.), 396: 643-649, 1998.
42. Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M., and Bos, J. L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med., 319: 525-532, 1988.
43. Sarmiere, P. D., and Freeman, R. S. Analysis of the NF-κB and PI 3-kinase/Akt survival pathways in nerve growth factor dependent neurons. Mol. Cell. Neurosci., 18: 320-331, 2001.
44. Wong, A. K., and Chin, L. An inducible melanoma model implicates a role for RAS in tumor maintenance and angiogenesis. Cancer Metastasis Rev., 19: 121-129, 2000.
45. Moody, S. E., Sarkisian, C. J., Hahn, K. T., Gunther, E. J., Pickup, S., Dugan, K. D., Innocent, N., Cardiff, R. D., Schnall, M. D., and Chodosh, L. A. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell, 2: 451-461, 2002.